David R. Spigel, MD, joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon's clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the Pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.
Dr. Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is a partner with Tennessee Oncology, PLLC.